公开(公告)号：US11345732B2

公开(公告)日：2022-05-31

申请号：US15758853

申请日：2016-09-09

Applicant: BEIJING BIO-TARGETING THERAPEUTICS TECHNOLOGY INC. ,  Zhengzhou University

Inventor： Yaohe Wang ,  Pengju Wang ,  Lemoine Nick ,  Dongling Gao

IPC: A61K35/76 ,  A61K35/761 ,  A61K35/768 ,  C07K14/54 ,  A61K48/00 ,  C12N15/863 ,  C12N15/861 ,  C12N15/869 ,  A61K38/20 ,  A61P35/00 ,  C12N15/86

Abstract: The present invention discloses a modified interleukin 12 (nsIL-12) and its gene, recombinant vector and use in manufacture of a medicament for treatment of tumors. When the oncolytic adenovirus vector carrying the modified interleukin 12 gene targets tumor tissue, the modified interleukin 12 is continuously expressed at a low level and mainly distributed in the local tumor tissue, which improves the specificity to tumor cells and reduces the systemic toxicity of interleukin 12; the modified interleukin 12 shows stronger inhibitory effect on tumor growth in intraperitoneally disseminated tumors and orthotopic tumors, and has low toxicity. The modified interleukin 12 armed oncolytic viruses show excellent anti-tumor effects, with a significant regression of tumors and lower toxicity compared with the existing IL-12 armed virus.

公开(公告)号：US20190010200A1

公开(公告)日：2019-01-10

申请号：US15758853

申请日：2016-09-09

Applicant: BEIJING BIO-TARGETING THERAPEUTICS TECHNOLOGY INC. ,  Zhengzhou University

Inventor： Yaohe Wang ,  Pengju Wang ,  Lemoine Nick ,  Dongling GAO

IPC: C07K14/54 ,  C12N15/86 ,  A61K35/761 ,  A61P35/00

Abstract: The present invention discloses a modified interleukin 12 (nsIL-12) and its gene, recombinant vector and use in manufacture of a medicament for treatment of tumors. When the oncolytic adenovirus vector carrying the modified interleukin 12 gene targets tumor tissue, the modified interleukin 12 is continuously expressed at a low level and mainly distributed in the local tumor tissue, which improves the specificity to tumor cells and reduces the systemic toxicity of interleukin 12; the modified interleukin 12 shows stronger inhibitory effect on tumor growth in intraperitoneally disseminated tumors and orthotopic tumors, and has low toxicity. The modified interleukin 12 armed oncolytic viruses show excellent antitumor effects, with a significant regression of tumors and lower toxicity compared with the existing IL-12 armed virus.

公开(公告)号：US20220213161A1

公开(公告)日：2022-07-07

申请号：US17700991

申请日：2022-03-22

Applicant: BEIJING BIO-TARGETING THERAPEUTICS TECHNOLOGY INC.

Inventor： Yaohe Wang ,  Pengju Wang ,  Lemoine Nick ,  Dongling GAO

IPC: C07K14/54 ,  A61K48/00 ,  C12N15/863 ,  C12N15/861 ,  C12N15/869 ,  A61K38/20 ,  A61P35/00 ,  A61K35/761 ,  C12N15/86

Abstract: The present invention discloses a modified interleukin 12 (nsIL-12) and its gene, recombinant vector and use in manufacture of a medicament for treatment of tumors. When the oncolytic adenovirus vector carrying the modified interleukin 12 gene targets tumor tissue, the modified interleukin 12 is continuously expressed at a low level and mainly distributed in the local tumor tissue, which improves the specificity to tumor cells and reduces the systemic toxicity of interleukin 12; the modified interleukin 12 shows stronger inhibitory effect on tumor growth in intraperitoneally disseminated tumors and orthotopic tumors, and has low toxicity. The modified interleukin 12 armed oncolytic viruses show excellent antitumor effects, with a significant regression of tumors and lower toxicity compared with the existing IL-12 armed virus.

公开(公告)号：US11306129B2

公开(公告)日：2022-04-19

申请号：US15758853

申请日：2016-09-09

Applicant: BEIJING BIO-TARGETING THERAPEUTICS TECHNOLOGY INC. ,  Zhengzhou University

Inventor： Yaohe Wang ,  Pengju Wang ,  Lemoine Nick ,  Dongling Gao

IPC: A61K35/76 ,  A61K35/761 ,  A61K35/768 ,  C07K14/54 ,  A61K48/00 ,  C12N15/863 ,  C12N15/861 ,  C12N15/869 ,  A61K38/20 ,  A61P35/00 ,  C12N15/86

Abstract: The present invention discloses a modified interleukin 12 (nsIL-12) and its gene, recombinant vector and use in manufacture of a medicament for treatment of tumors. When the oncolytic adenovirus vector carrying the modified interleukin 12 gene targets tumor tissue, the modified interleukin 12 is continuously expressed at a low level and mainly distributed in the local tumor tissue, which improves the specificity to tumor cells and reduces the systemic toxicity of interleukin 12; the modified interleukin 12 shows stronger inhibitory effect on tumor growth in intraperitoneally disseminated tumors and orthotopic tumors, and has low toxicity. The modified interleukin 12 armed oncolytic viruses show excellent anti-tumor effects, with a significant regression of tumors and lower toxicity compared with the existing IL-12 armed virus.